Quantitative analysis for Immunic, Inc. (IMUX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Hold (50.0) (grade C). 28 signals analyzed (23 differentiated alt-data).
IMUX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $10.75 | $9.98 | $10.03 |
| 2026-05-11 | $12.25 | $11.45 | $12.00 |
| 2026-05-21 | $12.49 | $10.87 | $12.30 |
| 2026-06-03 | $15.15 | $13.92 | $14.17 |
| 2026-06-15 | $14.40 | $13.51 | $14.01 |
| 2026-06-26 | $15.84 | $14.87 | $15.30 |
| 2026-07-09 | $15.44 | $14.61 | $14.78 |
| 2026-07-21 | $15.40 | $14.92 | $15.15 |
| 2026-07-31 | $14.18 | $13.43 | $13.97 |
| 2026-08-12 | $16.60 | $15.15 | $15.93 |
| 2026-08-24 | $16.83 | $16.06 | $16.46 |
| 2026-09-03 | $14.92 | $11.56 | $12.76 |
How Immunic, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CNTN | Canton Strategic Holdings Inc | $114M | — |
| FONR | FONAR Corporation | $117M | — |
| GNLX | Genelux Corporation | $110M | — |
| NAKA | Nakamoto Inc. | $110M | — |
View all Health Care stocks by valuation and signals →
Immunic, Inc. (IMUX) scores Hold (50.0), and the composite conceals a 68-point disagreement between its dimensions. It is strongest on analyst consensus at 69, and weakest on technicals at 26 and competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 69 |
| technicals | 26 |
| competitive moat | 1 |
StoQuant analyzes 28 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Immunic, Inc. (IMUX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/IMUX"><img src="https://stoquant.com/badge/IMUX.svg" alt="Immunic, Inc. (IMUX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.